Skip to main content

Oxidative Stress & Organ Health

Discovery Services

Select Service Type

CARDIOVASCULAR DISEASE & HYPERTENSION

  • Cytoprotection in endothelial cells (EAhy.926)DRF/CB/MD-20

    Cytoprotection in endothelial cells (EAhy.926) to evaluate CVS using endothelial cells (EAhy.926).

    • Cell Model

      Endothelial cells (EAhy.926)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      Atorvastatin calcium salt/ Simvastatin

    • Relevance

      CVS
  • Cytoprotection in cardiac cells (H9C2)DRF/CB/MD-21

    Cytoprotection in cardiac cells (H9C2) to evaluate CVS using cardiac cells (H9C2).

    • Cell Model

      cardiac cells (H9C2)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      Atorvastatin calcium salt/ Simvastatin

    • Relevance

      CVS
  • Anti-apoptotic effect against oxidative stressDRF/CB/MD-22

    Anti-apoptotic effect against oxidative stress to evaluate CVS using cardiac cells (H9C2).

    • Cell Model

      cardiac cells (H9C2)

    • End Point

      Anti-apoptotic potential against damage

    • Reference Drugs

      Atorvastatin calcium salt/ Simvastatin

    • Relevance

      CVS
  • Cytokine inhibition in endothelial cellsDRF/CB/MD-23

    Cytokine inhibition in endothelial cells to evaluate CVS using endothelial cells (EAhy.926).

    • Cell Model

      Endothelial cells (EAhy.926)

    • End Point

      Inhibition of cytokines as compared to damage

    • Reference Drugs

      Atorvastatin calcium salt/ Simvastatin

    • Relevance

      CVS
  • Inhibition of Lipid Overaccumulation in Macrophage cells by Oil Red O stainingDRF/CB/MD-24

    Inhibition of lipid overaccumulation in macrophage cells by Oil Red O staining to evaluate atherosclerosis using macrophages cell line (Raw.254).

    • Cell Model

      Macrophages cell line (Raw.254)

    • End Point

      Lipid Overaccumulation

    • Reference Drugs

      Atorvastatin calcium salt/ Simvastatin

    • Relevance

      Atherosclerosis
  • Angiotensin-converting enzyme (ACE) inhibitionDRF/CB/MD-25

    Angiotensin-converting enzyme (ACE) inhibition to evaluate vasodilation by measuring ACE inhibition.

    • Cell Model

      Cell-free

    • End Point

      ACE inhibition

    • Reference Drugs

      Atorvastatin calcium salt/ simvastatin

    • Relevance

      Vasodilation
  • Soluble Epoxide Hydrolase (sEH) inhibitionDRF/CB/MD-26

    Soluble Epoxide Hydrolase (sEH) inhibition to evaluate Vasodilation/Hypertension by measuring sEH inhibition.

    • Cell Model

      Cell-free

    • End Point

      sEH inhibition

    • Reference Drugs

      Atorvastatin calcium salt/ Simvastatin

    • Relevance

      Vasodilation/Hypertension
  • Cholesterol uptake in Macrophage cellsDRF/CB/MD-27

    Cholesterol uptake in macrophage cells to evaluate atherosclerosis using macrophages cell line (Raw.254).

    • Cell Model

      Macrophages cell line (Raw.254)

    • End Point

      Modulation of key biomarkers involved

    • Reference Drugs

      Atorvastatin calcium salt/ Simvastatin/ Metformin

    • Relevance

      Atherosclerosis

CARDIAC HEALTH

  • Cytoprotection in cardiac cells (H9C2) against oxidative stressDRF/CB/OH-01

    Cytoprotection in cardiac cells (H9C2) against oxidative stress to evaluate cardiac protection using cardiac cells (H9C2).

    • Cell Model

      Cardiac Cells (H9C2)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      L- Ascorbic Acid

    • Relevance

      Cardiac protection
  • Apoptosis in cardiac cells (H9C2) against oxidative stressDRF/CB/OH-02

    Apoptosis in cardiac cells (H9C2) against oxidative stress to evaluate cardiac protection using cardiac cells (H9C2).

    • Cell Model

      Cardiac Cells (H9C2)

    • End Point

      Anti-apoptotic potential against damage

    • Reference Drugs

      L- Ascorbic Acid

    • Relevance

      Cardiac protection
  • LDH in cardiac cells (H9C2) against oxidative stressDRF/CB/OH-03

    LDH in cardiac cells (H9C2) against oxidative stress to evaluate Cardiac protection using Cardiac Cells (H9C2).

    • Cell Model

      Cardiac Cells (H9C2)

    • End Point

      Inhibition in LDH levels as compared to damage

    • Reference Drugs

      Temozolomide/ N-Acetyl Cysteine

    • Relevance

      Cardiac protection
  • CKMB in cardiac cells (H9C2) against oxidative stressDRF/CB/OH-04

    CKMB in cardiac cells (H9C2) against oxidative stress to evaluate cardiac protection using cardiac Cells (H9C2).

    • Cell Model

      Cardiac Cells (H9C2)

    • End Point

      Inhibition in CKMB levels as compared to damage

    • Reference Drugs

      Temozolomide/ N-Acetyl Cysteine

    • Relevance

      Cardiac protection
  • Cytokine inhibition in cardiac cells (H9C2) against oxidative stressDRF/CB/OH-05

    Cytokine inhibition in cardiac cells (H9C2) against oxidative stress to evaluate cardiac protection using cardiac Cells (H9C2).

    • Cell Model

      Cardiac Cells (H9C2)

    • End Point

      Inhibition of cytokines as compared to damage

    • Reference Drugs

      Temozolomide/ N-Acetyl Cysteine

    • Relevance

      Cardiac protection
  • Biomarker analysis by multiplexingDRF/CB/OH-06

    Biomarker analysis by multiplexing to evaluate cardiac protection using cardiac cells (H9C2), measuring modulation of key biomarkers involved.

    • Cell Model

      Cardiac Cells (H9C2)

    • End Point

      Modulation of key biomarkers involved

    • Reference Drugs

      Temozolomide/ N-Acetyl Cysteine

    • Relevance

      Cardiac protection

LIVER HEALTH

  • Cytoprotection in liver cells (HEPG2) against oxidative stressDRF/CB/OH-07

    Cytoprotection in liver cells (HEPG2) against oxidative stress to evaluate hepatoprotection using Hepatocytes (HepG2).

    • Cell Model

      Hepatocytes (HepG2)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      Silymarin

    • Relevance

      Hepatoprotection
  • Apoptosis in liver cells (HEPG2) against oxidative stressDRF/CB/OH-08

    Apoptosis in liver cells (HEPG2) against oxidative stress to evaluate hepatoprotection using Hepatocytes (HepG2).

    • Cell Model

      Hepatocytes (HepG2)

    • End Point

      Anti-apoptotic potential against damage

    • Reference Drugs

      Silymarin

    • Relevance

      Hepatoprotection
  • Albumin in liver cells (HEPG2) against oxidative stressDRF/CB/OH-09

    Albumin in liver cells (HEPG2) against oxidative stress to evaluate hepatoprotection using Hepatocytes (HepG2).

    • Cell Model

      Hepatocytes (HepG2)

    • End Point

      Albumin levels

    • Reference Drugs

      Silymarin

    • Relevance

      Hepatoprotection
  • SGOT/SGPT in liver cells (HEPG2) against oxidative stressDRF/CB/OH-10

    SGOT/SGPT in liver cells (HEPG2) against oxidative stress to evaluate hepatoprotection using Hepatocytes (HepG2).

    • Cell Model

      Hepatocytes (HepG2)

    • End Point

      Inhibition of SGOT/SGPT as compared to damage

    • Reference Drugs

      Silymarin

    • Relevance

      Hepatoprotection
  • Cytokine inhibition in liver cells (HEPG2) against oxidative stressDRF/CB/OH-11

    Cytokine inhibition in liver cells (HEPG2) against oxidative stress to evaluate hepatoprotection using Hepatocytes (HepG2).

    • Cell Model

      Hepatocytes (HepG2)

    • End Point

      Inhibition of cytokines as compared to damage

    • Reference Drugs

      Silymarin

    • Relevance

      Hepatoprotection
  • SOD, SGT, LPO, Catalase inhibition in liver cells (HEPG2) against oxidative stressDRF/CB/OH-12

    SOD, SGT, LPO, Catalase inhibition in liver cells (HEPG2) against oxidative stress to evaluate hepatoprotection using Hepatocytes (HepG2).

    • Cell Model

      Hepatocytes (HepG2)

    • End Point

      SOD, SGT, LPO, Catalase levels

    • Reference Drugs

      Silymarin

    • Relevance

      Hepatoprotection
  • Biomarker analysis by multiplexingDRF/CB/OH-13

    Biomarker analysis by multiplexing to evaluate hepatoprotection using Hepatocytes (HepG2), measuring modulation of key biomarkers involved.

    • Cell Model

      Hepatocytes (HepG2)

    • End Point

      Modulation of key biomarkers involved

    • Reference Drugs

      Silymarin

    • Relevance

      Hepatoprotection

LIVER CIRRHOSIS

  • Anti-fibrotic activity in Hepatic Stellate Cells by in inhibition of proliferationDRF/CB/OH-14

    Anti-fibrotic activity in Hepatic Stellate Cells by in inhibition of proliferation to evaluate Anti-cirrhosis using Stellate cells (HSTC-6).

    • Cell Model

      Stellate cells (HSTC-6)

    • End Point

      Inhibition of proliferation

    • Reference Drugs

      Silymarin

    • Relevance

      Anti-cirrhosis
  • Collagen inhibition in Hepatic Stellate CellsDRF/CB/OH-15

    Collagen inhibition in Hepatic Stellate Cells to evaluate Anti-cirrhosis using stellate cells (HSTC-6).

    • Cell Model

      Stellate cells (HSTC-6)

    • End Point

      Inhibition of Collagen synthesis

    • Reference Drugs

      Silymarin

    • Relevance

      Anti-cirrhosis
  • TGF-β inhibition in Hepatic Stellate CellsDRF/CB/OH-16

    TGF-β inhibition in Hepatic Stellate Cells to evaluate Anti-cirrhosis using Stellate cells (HSTC-6).

    • Cell Model

      Stellate cells (HSTC-6)

    • End Point

      TGF-β inhibition

    • Reference Drugs

      Silymarin

    • Relevance

      Anti-cirrhosis
  • Apoptosis in Hepatic Stellate CellsDRF/CB/OH-17

    Apoptosis in Hepatic Stellate Cells to evaluate anti-cirrhosis using stellate cells (HSTC-6).

    • Cell Model

      Stellate cells (HSTC-6)

    • End Point

      Apoptosis by Mitochondrial membrane potential, cell cycle analysis, Annexin V staining

    • Reference Drugs

      Silymarin

    • Relevance

      Anti-cirrhosis

KIDNEY HEALTH

  • Cytoprotection in kidney cells (HEK-293) against oxidative stressDRF/CB/OH-18

    Cytoprotection in kidney cells (HEK-293) against oxidative stress to evaluate nephroprotection using Kidney cells (HEK293).

    • Cell Model

      Kidney cells (HEK293)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      Quercetin

    • Relevance

      Nephroprotection
  • Apoptosis in kidney cells (HEK-293) against oxidative stressDRF/CB/OH-19

    Apoptosis in kidney cells (HEK-293) against oxidative stress to evaluate nephroprotection using kidney cells (HEK293).

    • Cell Model

      Kidney cells (HEK293)

    • End Point

      Anti-apoptotic potential against damage

    • Reference Drugs

      Quercetin

    • Relevance

      Nephroprotection
  • Cytokine inhibition in kidney cells (HEK-293) against oxidative stressDRF/CB/OH-20

    Cytokine inhibition in kidney cells (HEK-293) against oxidative stress to evaluate nephroprotection using kidney cells (HEK293).

    • Cell Model

      Kidney cells (HEK293)

    • End Point

      Inhibition of cytokines as compared to damage

    • Reference Drugs

      Dexamethasone

    • Relevance

      Nephroprotection
  • Biomarker analysis by multiplexingDRF/CB/OH-21

    Biomarker analysis by multiplexing to evaluate Nephroprotection using Kidney cells (HEK293).

    • Cell Model

      Kidney cells (HEK293)

    • End Point

      Modulation of key biomarkers involved

    • Reference Drugs

      Dexamethasone

    • Relevance

      Nephroprotection

LUNG HEALTH

  • Cytoprotection in lung cells (A549) against oxidative stressDRF/CB/OH-26

    Cytoprotection in lung cells (A549) against oxidative stress to evaluate lung protection using Lung epithelial cells (A549).

    • Cell Model

      Lung Epithelial Cells (A549)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      Quercetin

    • Relevance

      Lung protection
  • Apoptosis in lung cells (A549) against oxidative stressDRF/CB/OH-27

    Apoptosis in lung cells (A549) against oxidative stress to evaluate Lung protection using Lung Epithelial Cells (A549).

    • Cell Model

      Lung Epithelial Cells (A549)

    • End Point

      Anti-apoptotic potential against damage

    • Reference Drugs

      Quercetin

    • Relevance

      Lung protection
  • Cytokine inhibition in lung cells (A549) against oxidative stressDRF/CB/OH-28

    Cytokine inhibition in lung cells (A549) against oxidative stress to evaluate lung protection using lung epithelial Cells (A549).

    • Cell Model

      Lung Epithelial Cells (A549)

    • End Point

      Inhibition of cytokines as compared to damage

    • Reference Drugs

      Quercetin

    • Relevance

      Lung protection
  • Biomarker analysis by multiplexingDRF/CB/OH-29

    Biomarker analysis by multiplexing to evaluate Lung protection using Leung Epithelial Cells (A549).

    • Cell Model

      Lung Epithelial Cells (A549)

    • End Point

      Modulation of key biomarkers involved

    • Reference Drugs

      Quercetin

    • Relevance

      Lung protection

PANCREATIC HEALTH

  • Cytoprotection in pancreatic cells (PANC-1) against oxidative stressDRF/CB/OH-30

    Cytoprotection in pancreatic cells (PANC-1) against oxidative stress to evaluate Pancreatic protection using pancreatic cells (PANC-1).

    • Cell Model

      Pancreatic cells (PANC-1)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      Quercetin/ Silymarin

    • Relevance

      Pancreatic protection
  • Apoptosis in pancreatic cells (PANC-1) against oxidative stressDRF/CB/OH-31

    Apoptosis in pancreatic cells (PANC-1) against oxidative stress to evaluate pancreatic protection using pancreatic cells (PANC-1).

    • Cell Model

      Pancreatic cells (PANC-1)

    • End Point

      Anti-apoptotic potential against damage

    • Reference Drugs

      Quercetin/ Silymarin

    • Relevance

      Pancreatic protection
  • Cytokine inhibition in pancreatic cells (PANC-1) against oxidative stressDRF/CB/OH-32

    Cytokine inhibition in pancreatic cells (PANC-1) against oxidative stress to evaluate pancreatic protection using pancreatic cells (PANC-1).

    • Cell Model

      Pancreatic cells (PANC-1)

    • End Point

      Inhibition of cytokines as compared to damage

    • Reference Drugs

      Quercetin/ Silymarin

    • Relevance

      Pancreatic protection
  • Biomarker analysis by multiplexingDRF/CB/OH-33

    Biomarker analysis by multiplexing to evaluate pancreatic protection using pancreatic cells (PANC-1).

    • Cell Model

      Pancreatic cells (PANC-1)

    • End Point

      Modulation of key biomarkers involved

    • Reference Drugs

      Quercetin/ Silymarin

    • Relevance

      Pancreatic protection

ORAL MUCOSITIS

  • Cytoprotection in buccal cells against chemotherapy/radiation induced damageDRF/CB/OM-01

    Cytoprotection in buccal cells against chemotherapy/radiation induced damage using buccal mucosa cells.

    • Cell Model

      Buccal Mucosa (TR146)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      EGCG/ Amifostine

    • Relevance

      Anti-mucositis
  • Anti-apoptotic effect in buccal cells against chemotherapy/radiation induced damageDRF/CB/OM-02

    Anti-apoptotic effect in buccal cells against chemotherapy/radiation induced damage using buccal mucosa cells.

    • Cell Model

      Buccal Mucosa (TR146)

    • End Point

      Anti-apoptotic potential against damage

    • Reference Drugs

      Amifostine

    • Relevance

      Anti-mucositis
  • Cytokine inhibition in buccal cells against chemotherapy/radiation induced damageDRF/CB/OM-03

    Cytokine inhibition in buccal cells against chemotherapy/radiation induced damage using buccal mucosa cells.

    • Cell Model

      Buccal Mucosa (TR146)

    • End Point

      Inhibition of cytokines as compared to damage

    • Reference Drugs

      Amifostine

    • Relevance

      Anti-mucositis
  • Biomarker analysis by multiplexingDRF/CB/OM-04

    Biomarker analysis by multiplexing to evaluate modulation of key biomarkers.

    • Cell Model

      Buccal Mucosa (TR146)

    • End Point

      Modulation of key biomarkers involved

    • Reference Drugs

      Amifostine

    • Relevance

      Anti-mucositis

ORAL CARE

  • Cytoprotection against oxidative damage in gingival fibroblastsDRF/CB/OC-01

    Cytoprotection against oxidative damage in gingival fibroblasts using human gingival fibroblast measuring restoration if cell viability.

    • Cell Model

      Human Gingival Fibroblast (HGF)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      α- Tocopherol

    • Relevance

      Gingivitis/Antioxidant for gum health
  • Apoptosis in gingival fibroblastsDRF/CB/OC-02

    Apoptosis in gingival fibroblasts using human gingival fibroblast.

    • Cell Model

      Human Gingival Fibroblast (HGF)

    • End Point

      Anti-apoptotic potential against damage

    • Reference Drugs

      α- Tocopherol

    • Relevance

      Gingivitis/Antioxidant for gum health
  • Migration in gingival fibroblastsDRF/CB/OC-03

    Migration in gingival fibroblasts to measure percent modulation of migration.

    • Cell Model

      Human Gingival Fibroblast (HGF)

    • End Point

      Percent modulation of migration

    • Reference Drugs

      α- Tocopherol

    • Relevance

      Gingivitis/Antioxidant for gum health
  • Cytokines inhibition in gingival fibroblastsDRF/CB/OC-04

    Cytokines inhibition in gingival fibroblasts to measure cytokine inhibition.

    • Cell Model

      Human Gingival Fibroblast (HGF)

    • End Point

      Cytokine inhibition

    • Reference Drugs

      α- Tocopherol

    • Relevance

      Gingivitis/Antioxidant for gum health

ANTIOXIDANT

  • ABTS radical scavengingDRF/CB/AO-01

    ABTS radical scavenging to evaluate free radical scavenging potential using cell free assay.

    • Cell Model

      Cell free assay

    • End Point

      Free radical scavenging potential

    • Reference Drugs

      Ascorbic acid/Trolox

    • Relevance

      Free radical scavenging potential
  • DPPH radical scavengingDRF/CB/AO-02

    DPPH radical scavenging to evaluate free radical scavenging potential using cell free assay.

    • Cell Model

      Cell free assay

    • End Point

      Free radical scavenging potential

    • Reference Drugs

      Ascorbic acid/Trolox

    • Relevance

      Free radical scavenging potential

Cardiac Health

  • L-NAME and High Fat Diet -induced cardiac abnormalities usingPCY/CH-01

    L-NAME and high-fat diet-induced cardiac abnormalities model in rats, assessing blood pressure, lipid profile, serum cytokines, and histology of vital organs.

    • Animal Model

      Wistar/SD Rats

    • End Point

      Blood pressure,Lipid profile,Serum cytokines,Histology of vital organs

    • Reference Drugs

      Atorvastatin + Captopril
  • Uninephrectomy induced hypertension modelPCY/CH-02

    Uninephrectomy-induced hypertension model in rats, measuring systolic, diastolic, mean blood pressure, and body weight.

    • Animal Model

      Wistar/SD Rats

    • End Point

      Systolic,Diastolic,Mean Blood Pressure,Body weight

    • Reference Drugs

      `--

Lung Health

  • Bleomycin induced lung fibrosis modelPCY/LU-01

    Bleomycin-induced lung fibrosis model in mice, assessing BALF cytokine levels (IL-1β and TNF-α), lung biomarkers, and histology.

    • Animal Model

      C57BL6 Mice

    • End Point

      BALF - cytokine (IFN-γ and TNF-α ), Lung biomarker (TGF beta, IL1 beta),Histology of Lung

    • Reference Drugs

      Pirfenidone
  • Pollutant (PM2.5/Ovalbumin/LPS) induced lung inflammation modelPCY/LU-02

    Pollutant (PM2.5/Ovalbumin/LPS)-induced lung inflammation model in mice, measuring cytokine levels in BALF and lung histology.

    • Animal Model

      BALB/c Mice

    • End Point

      Cytokine (TNF-α , IL6, IgE, etc.) level in BALF & Lung,Histology of Lung

    • Reference Drugs

      `--

Liver Health

  • Hepatoprotective activity using CCl4 induction modelPCY/LH-01

    Hepatoprotective activity using CCl4 induction model in rats/mice, assessing SGOT, SGPT, bilirubin, GGT, body weight, and liver histology.

    • Animal Model

      Wistar, SD Rat/ Swiss Albino Mice

    • End Point

      SGOT, SGPT, Bilirubin, GGT, Body weight, feed consumption,Liver histology

    • Reference Drugs

      Silymarin
  • Hepatoprotective activity using Ethanol induction modelPCY/LH-02

    Hepatoprotective activity using ethanol induction model in rats/mice, measuring SGOT, SGPT, bilirubin, GGT, and liver histology.

    • Animal Model

      Wistar, SD Rat/ Swiss Albino Mice

    • End Point

      SGOT, SGPT, Bilirubin, GGT, Body weight,Feed consumption,Liver histology

    • Reference Drugs

      Silymarin
  • Hepatoprotective activity using Paracetamol induction modelPCY/LH-03

    Hepatoprotective activity using paracetamol induction model in rats/mice, assessing liver function markers (SGOT, SGPT, bilirubin, GGT), and liver histology.

    • Animal Model

      Wistar, SD Rat/ Swiss Albino Mice

    • End Point

      SGOT, SGPT, Bilirubin, GGT, Body weight,Feed consumption,Liver histology

    • Reference Drugs

      Silymarin
  • Con-A induced Liver inflammation modelPCY/LH-04

    Concanavalin A (Con-A)-induced liver inflammation model in mice, measuring liver enzymes, cytokines (IFN-γ and TNF-α), and liver histology.

    • Animal Model

      BALB/c Mice

    • End Point

      SGOT, SGPT, Bilirubin, GGT, Serum Cytokines (IL-1β, IFN-γ and TNF-α),Liver histology

    • Reference Drugs

      Silymarin

Kidney Health

  • Nephroprotective Activity using Gentamycin induced model PCY/KH-01

    Nephroprotective activity using gentamycin-induced nephrotoxicity model in rats, assessing kidney function tests, kidney histology, and urinalysis.

    • Animal Model

      Wistar/SD Rat

    • End Point

      Kidney function test, Histology of kidney,Urinalysis

    • Reference Drugs

      `--
  • Diabetes induced Nephropathy modelPCY/KH-02

    Diabetes-induced nephropathy model in rats, measuring kidney function tests, urinalysis, and glomerular filtration rate (GFR).

    • Animal Model

      Wistar/ SD Rats

    • End Point

      Kidney function test,Histology of kidney,Urinalysis,Glomerular filtration rate

    • Reference Drugs

      `--

Ophthalmology

  • Sodium selenite-induced cataract model PCY/OP-01

    Sodium selenite-induced cataract model in rat pups, measuring cataract grade, opacity score, and slit lamp examination.

    • Animal Model

      Rat Pups

    • End Point

      Cataract grade, Opacity score of isolated lens, Slit lamp examination

    • Reference Drugs

      `--
  • Cornea damage model PCY/OP-02

    Cornea damage model in New Zealand rabbits, assessing OCT imaging, slit lamp examination, histology, and intraocular pressure.

    • Animal Model

      New Zealand Rabbit

    • End Point

      OCT imaging, Slit lamp examination, Histology, Intraocular Pressure

    • Reference Drugs

      `--
  • Intraocular Pressure modelPCY/OP-03

    Intraocular pressure model in New Zealand rabbits, measuring OCT imaging, slit lamp examination, and intraocular pressure.

    • Animal Model

      New Zealand Rabbit

    • End Point

      OCT imaging, Slit lamp examination, Histology, Intraocular Pressure

    • Reference Drugs

      `--
  • Diabetes induced cataract and Retinopathy model PCY/OP-04

    Diabetes-induced cataract and retinopathy model in rats, assessing OCT imaging, slit lamp examination, and intraocular pressure.

    • Animal Model

      Wistar/SD Rats

    • End Point

      OCT imaging, Slit lamp examination, Histology, Intraocular Pressure

    • Reference Drugs

      `--
  • BAC- induced Dry eye model PCY/OP-05

    BAC-induced dry eye model in mice, measuring OCT imaging, slit lamp examination, tear volume, and intraocular pressure.

    • Animal Model

      BALB/c Mice

    • End Point

      OCT imaging, Slit lamp examination, Histology, Intraocular Pressure,Tear Volume

    • Reference Drugs

      Restasis

Oral Health

  • 5-FU & Physical damage induced mucositis model PCY/CH-01

    5-FU & Physical damage-induced mucositis model assessing mucosal scoring, imaging, cheek pouch histology, and cytokine estimation.

    • Animal Model

      Rat, Hamster

    • End Point

      Mucosal scoring, Imagining, Histology of cheek pouch, Cytokine estimation

    • Reference Drugs

      Dexamethazone
  • Carrageenan induced gingivitis model in ratsPCY/CH-01

    Carrageenan-induced gingivitis model in rats assessing pain via Rat Grimace Scale, warm water consumption sensitivity, food consumption, gingivitis scoring, Von Frey test, actophotometer readings, and mouth cavity histopathology

    • Animal Model

      Rat

    • End Point

      Pain Assessment by Rat Grimace Scale, Warm Water Consumption Sensitivity Test, Food Consumption, Gingivitis Scoring, Von Frey Test, Actophotometer and Histopathology of of Mouth Cavity

    • Reference Drugs

      Ketorolac